🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Violeta Serra

Hebron University

ORCID: 0000-0001-6620-1065

Also affiliated with Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer”.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast Cancer Research(2020)10.1186/s13058-020-01354-y

N/A

3.0DataRank · unranked

148 citations

Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo +18 more

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Nature Genetics(2021)10.1038/s41588-020-00750-6

N/A

0.790DataRank · unranked

193 citations

Jessica Giordano, Anuj Srivastava, Min Jin Ha, Michael W. Lloyd, Roebi de Bruijn +57 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0.721DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

Genome Medicine(2020)10.1186/s13073-020-00774-x

N/A

0DataRank · unranked

23 citations

Miquel Duran‐Frigola, Albert Gris‐Oliver, Marta Palafox, Maurizio Scaltriti, Pedram Razavi +6 more

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1726

N/A

0DataRank · unranked

166 citations

Baishan Jiang, Jiaye Guo, Hong Shao, Isabella Del Priore, Qing Chang +20 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3324

N/A

0DataRank · unranked

41 citations

Marta Palafox, Laia Monserrat, Fara Brasó‐Maristany, Andreu Òdena, Mònica Sánchez-Guixé +26 more

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Cancer Research(2022)10.1158/0008-5472.can-21-2409

N/A

0DataRank · unranked

98 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3335

N/A

0DataRank · unranked

65 citations

Lillian N. van Biljon, Mark C. Valentine, Alba Llop‐Guevara, Emily Graham, Bisiayo Fashemi +18 more

Data from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2023)10.1158/0008-5472.c.6497889

N/A

0DataRank · unranked

0 citations

Magüi Gili, Maurizio Scaltriti, Violeta Serra, Marta Guzmán, Wouter Nijkamp +6 more

Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

(2023)10.1158/0008-5472.c.6513876.v1

N/A

0DataRank · unranked

0 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer

Journal of Clinical Investigation(2025)10.1172/jci189511

N/A

0DataRank · unranked

7 citations

Amanda Compadre, Rebecca Drexler, Megan Loeb, Kevin Rodriguez, Joshua Brill +22 more